Patches giving oestrogen through the skin could be an easy and
safe alternative to hormone therapies used to treat prostate
cancer, according to new research from Imperial College
London.
The study found that oestrogen patches, usually used to treat
menopause symptoms in women, reduced levels of testosterone in men
to a similar extent as the current hormone treatment, LHRHa
injections.
Many prostate cancers need the male hormone testosterone to
grow. Using drugs to reduce testosterone in advanced stages of the
disease can shrink the tumour or slow
growth.
In the 1960s this was done by using oestrogen tablets, but this
caused heart and blood clotting side effects for some men.
Now, LHRHa injections are the main treatment for reducing
testosterone but these may also cause serious side effects
including hot flushes, osteoporosis, bone fractures and
diabetes.
The Imperial researchers collaborated with colleagues at the
Medical Research Council Clinical Trials Unit and clinicians at
Imperial College Healthcare NHS Trust. The work was funded by
Cancer Research UK.
The team compared LHRHa injections to oestrogen patches in 254
men with locally advanced prostate cancer or prostate cancer that
had spread, in order to test the benefits and side effects from the
patches.
The results showed that patches appeared to suppress
testosterone levels to a similar extent as LHRHa injections. After
12 months, the researchers also found that those having the LHRHa
treatment had higher blood glucose and cholesterol levels, which
can increase the risk of heart disease, compared to men treated
with patches. The patches did not cause the same degree of heart
and blood clotting problems caused by oestrogen
tablets.
The initial trial has now been extended to study the long-term
effectiveness and side effects of oestrogen patches in a larger
group of 660 men.
Dr Ruth Langley, from the Medical Research Council Clinical
Trials Unit, said: "These promising new findings suggest that we
might be able to use oestrogen patches or an oestrogen gel to treat
prostate cancer without significantly increasing the risk of heart
disease and stroke. We think the reason oral oestrogen causes these
side effects is because the oestrogen reaches the liver in high
concentrations straight from the stomach, whereas if the oestrogen
can be absorbed through the skin, the effect on the liver is
avoided."
Professor Paul Abel, from Imperial College London and an
honorary consultant in urology at Imperial College Healthcare,
said: "The next step is to test if the oestrogen patches are as
effective at stopping the growth of prostate cancer as the current
hormone treatments. We're now testing this in over 600 patients and
early results are expected later this year."
Kate Law, director of clinical and population research at Cancer
Research UK, said: "More men than ever are surviving prostate
cancer thanks to advances in research, but we still urgently need
to find more effective treatments and reduce side effects. This
trial is an important step towards better and kinder treatments
that could bring big benefits to men with prostate cancer in the
future."
The paper, Cardiovascular outcomes in patients with locally advanced and
metastatic prostate cancer treated with
luteinising-hormone-releasing-hormone agonists or transdermal
oestrogen: the randomised, phase 2 MRC PATCH trial (PR09), is
published in The Lancet
Oncology.